Quest Diagnostics Incorporated (DGX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Quest Diagnostics Incorporated

NYSE•Healthcare•Diagnostics & Research

$251.82-1.10(<0.01%)Market closed

Market Cap

$27.46B

P/E

24.3x

P/S

2.3x

P/B

3.6x

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

How this company scores

GoodMetricSide Score: 74/100

Strongest: Profitability (21/25); weakest: Balance Sheet & Red Flags (14/25).

Profitability21/25

Growth21/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality18/25

Strengths

Rising earningsCash-backed earningsConsistent free cash flowProfit converts from growth

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 24.3x5y range 8.8x – 24.3x

Currently above its 20-quarter median.

P/S · 2.3x5y range 1.4x – 2.3x

Currently above its 20-quarter median.

P/B · 3.6x5y range 2.1x – 3.6x

Price & Volume

Market Cap $27.46B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $11.84B
Q. Revenue: $3.10B
TTM EBITDA: $2.31B
TTM Op. Income: $1.72B
Q. Op. Income: $479.00M
TTM Net Income: $1.13B
Q. Net Income: $312.00M
EPS: $2.82
Shares Out.: $110.00M

$11.84B in TTM revenue grew 9.1% YoY, reaching $3.10B last quarter. TTM EBITDA of $2.31B and TTM operating income of $1.72B show growth is flowing through to the bottom line. TTM net income of $1.13B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 33.6%
EBITDA Margin: 20.2%
Op. Margin: 15.5%
Net Margin: 10.1%

Op. margin of 15.5% is up 1.8% YoY — cost efficiency is improving. Net margin at 10.1% and gross margin of 33.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 4 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 24.3x
P/S Ratio: 2.3x
P/B Ratio: 3.6x

At 24.3x P/E, the stock trades within typical market levels. P/S of 2.3x and P/B of 3.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 3 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $17.22B
Cash: $797.00M
Long-Term Debt: $5.54B
Book Value: $7.63B
D/E Ratio: 0.7
Debt/EBITDA: 8.8

With $17.22B in assets and $5.54B in long-term debt, D/E is 0.7and book value is $7.63B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 2% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $611.00M
TTM Free Cash Flow: $1.38B
FCF Margin: 11.6%
FCF / Net Income: 1.2

TTM FCF of $1.38B on $611.00M in operating cash flow. The FCF / Net Income ratio of 1.2x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.